Researchers at Stanford have developed a new catalog of compact transcription effector domains and fused them onto DNA binding domains to engineer synthetic transcription factors.
Stanford researchers have identified a biomarker on cartilage precursor cells that can predict which cells will develop into inflammation-resistant and functionally appropriate tissue for autologous transplants to treat osteoarthritis.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an efficacious therapy for patients with life-threatening leukemias, but its use has been hindered by the limited availability of donors with matching HLA. Graft manipulation by removing ??
Researchers in Prof. Karl Deisseroth's laboratory have combined optogenetics with functional magnetic resonance imaging (fMRI) to enable highly specific in vivo analysis of brain circuits.
Researchers in Prof. Karl Deisseroth's laboratory have used optogenetic tools to develop an animal model for cocaine-modulated behavior modification by precisely targeting defined neural circuit elements.
Researchers in Prof. Karl Deisseroth's laboratory have engineered a novel channelrhodopsin with enhanced expression, faster speed, and improved targeting.
Researchers in Prof. Karl Deisseroth's laboratory have used optogenetic tools to develop a precise, specific and inexpensive animal model of impaired memory.
Researchers in Prof. Karl Deisseroth's laboratory have identified a unifying endophenotype for psychosis that could be used to develop antipsychotic treatments.
Researchers in Prof. Karl Deisseroth's laboratory have used optogenetic tools to develop an animal model for social dysfunction by precisely targeting defined neural circuit elements.
Researchers in Prof. Karl Deisseroth's laboratory have used optogenetic tools to develop an animal model for anxiety by precisely identifying, creating, resolving, and targeting defined neural circuit elements.
Researchers from Prof. Karl Deisseroth's laboratory have developed techniques for specifically modulating the activity of excitable cells in vivo. This approach introduces light-responsive proteins to create photo-sensitive cells.
Researchers in Dr. Karl Deisseroth's laboratory at Stanford University have developed a novel suite of genetically-encodable, optically-activated modulators of second messengers (such as cAMP and IP3).
The inventors have developed a light-driven chloride pump (NpHR or Halo) for temporally precise optical inhibition of neural activity with ordinary yellow light.